LUXTURNA Sales Forecast and Market Size Analysis 2020-2034 | Innovative Reimbursement Models Expand Patient Access

LUXTURNA Sales Forecast and Market Size Analysis 2020-2034 | Innovative Reimbursement Models Expand Patient Access Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "LUXTURNA Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.

The report provides a comprehensive assessment of LUXTURNA (voretigene neparvovec) across the seven major markets: the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. It examines historical performance, current utilization, market trends, competitive positioning, and forecast sales from 2020 through 2034 for approved RPE65 mutation-associated retinal dystrophies, including Leber congenital amaurosis and certain forms of retinitis pigmentosa.

Key Factors Driving LUXTURNA Market Growth

LUXTURNA is a first-in-class, one-time AAV2 vector-based gene therapy designed to deliver a functional copy of the RPE65 gene to retinal pigment epithelial cells. Its ability to address the underlying genetic cause of disease differentiates it from chronic supportive treatments and represents a significant driver of adoption among eligible patients with confirmed biallelic RPE65 mutations and sufficient viable retinal cells.

The eligible population remains small, with estimates of approximately 1,000-2,000 patients in the United States and nearly 6,000 worldwide. However, LUXTURNA's premium pricing model supports substantial revenue per treated patient. The reported US list price is approximately USD 850,000 for treatment of both eyes, although realized costs may vary according to reimbursement agreements, treatment setting, and geography.

Outcome-based reimbursement arrangements and alternative payment models have helped address payer concerns related to the therapy's high upfront cost. These approaches may improve patient access while linking reimbursement to clinical outcomes. Commercialization is supported by Spark Therapeutics, a Roche company, in the United States and by Novartis in markets outside the United States.

LUXTURNA Drug and Clinical Overview

LUXTURNA received US Food and Drug Administration approval in 2017 for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The recommended dose is 1.5 10 11 vector genomes per eye, administered in a total subretinal volume of 0.3 mL. Each eye is treated during a separate surgical procedure performed at least six days apart.

Administration is restricted to qualified treatment centers with appropriate surgical capabilities. Reported risks include intraocular inflammation, retinal abnormalities, increased intraocular pressure, cataracts, retinal tears, and endophthalmitis. Perioperative corticosteroid therapy is used as part of treatment management. Long-term follow-up data continue to support durable functional vision gains in a substantial proportion of treated patients, although outcomes may vary.

Scope of the LUXTURNA Market Report

LUXTURNA Market Potential and Competitive Landscape

The report evaluates LUXTURNA's projected market size, peak sales potential, pricing strategy, reimbursement environment, and positioning within the inherited retinal disease treatment landscape. It also assesses pipeline therapies that could affect future demand, including competing gene therapies and other advanced modalities in development for Leber congenital amaurosis and retinal dystrophies.

LUXTURNA's established regulatory position, durable clinical results, and first-mover advantage support its commercial outlook. Nevertheless, market expansion may be constrained by the limited eligible population, requirements for genetic confirmation, treatment-center capacity, surgical complexity, high acquisition costs, and the emergence of competing therapies. Identification of previously undiagnosed patients and broader access to genetic testing may influence future uptake.

Report Methodology

The LUXTURNA market forecast is developed through internal databases, primary research, secondary research, and analysis by industry experts. Sources include regulatory authority publications, clinical trial registries, company disclosures, peer-reviewed journals, trade publications, industry associations, market databases, and relevant news sources. The analysis integrates clinical, regulatory, epidemiological, pricing, reimbursement, and commercial data to support market projections through 2034.

Key Strategic Questions Addressed

The report delivers actionable insights for pharmaceutical companies, investors, healthcare organizations, market-access teams, and other stakeholders evaluating LUXTURNA's long-term clinical and commercial potential. Its detailed sales forecasts, competitive assessment, and regional market analysis support strategic planning, portfolio management, reimbursement decisions, and investment evaluation within the inherited retinal disease market.

Key Topics Covered

1. Report Introduction

2. LUXTURNA Overview in approved indications like Leber congenital amaurosis and Retinal dystrophies

2.1. Product Detail

2.2. LUXTURNA Clinical Development

2.2.1. LUXTURNA Clinical studies

2.2.2. LUXTURNA Clinical trials information

2.2.3. Safety and efficacy

2.3. Other Developmental Activities

2.4. Product Profile

3. LUXTURNA Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging LUXTURNA Therapies)

5. LUXTURNA Market Assessment

5.1. LUXTURNA Market Outlook in approved indications

5.2. 7MM Analysis

5.2.1. LUXTURNA Market Size in the 7MM for approved indications

5.3. Country-wise Market Analysis

5.3.1. LUXTURNA Market Size in the United States for approved indications

5.3.2. LUXTURNA Market Size in Germany for approved indications

5.3.3. LUXTURNA Market Size in France for approved indications

5.3.4. LUXTURNA Market Size in Italy for approved indications

5.3.5. LUXTURNA Market Size in Spain for approved indications

5.3.6. LUXTURNA Market Size in the United Kingdom for approved indications

5.3.7. LUXTURNA Market Size in Japan for approved indications

6. LUXTURNA SWOT Analysis

7. Analyst's Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

List of Tables

Table 1: LUXTURNA, Clinical Trial Description, 2023

Table 2: LUXTURNA, General Description

Table 3: Competitive Landscape (Marketed Therapies)

Table 4: Competitive Landscape (Emerging Therapies)

Table 5: LUXTURNA's pricing and cost Assumptions

Table 6: LUXTURNA's Sales Analysis in the 7MM, in USD million (2020-2034)

Table 7: LUXTURNA Market Size in the US, in USD million (2020-2034)

Table 8: LUXTURNA Market Size in Germany, in USD million (2020-2034)

Table 9: LUXTURNA Market Size in France, in USD million (2020-2034)

Table 10: LUXTURNA Market Size in Italy, in USD million (2020-2034)

Table 11: LUXTURNA Market Size in Spain, in USD million (2020-2034)

Table 12: LUXTURNA Market Size in the UK, in USD million (2020-2034)

Table 13: LUXTURNA Market Size in Japan, in USD million (2020-2034)

List of Figures

Figure 1: LUXTURNA's Sales Analysis in the 7MM, USD million (2020-2034)

Figure 2: LUXTURNA Market Size in the United States, USD million (2020-2034)

Figure 3: LUXTURNA Market Size in Germany, USD million (2020-2034)

Figure 4: LUXTURNA Market Size in France, USD million (2020-2034)

Figure 5: LUXTURNA Market Size in Italy, USD million (2020-2034)

Figure 6: LUXTURNA Market Size in Spain, USD million (2020-2034)

Figure 7: LUXTURNA Market Size in the United Kingdom, USD million (2020-2034)

Figure 8: LUXTURNA Market Size in Japan, USD million (2020-2034)

For more information about this report visit https://www.researchandmarkets.com/r/j2bkxd

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.